As one of the first studies testing perioperative anti-PD-(L)1 antibodies in resectable non-small-cell lung cancer (NSCLC), NADIM now confirms, in its final report, impressive 5-year clinical outcomes and that a pCR following neoadjuvant therapy translates into improved long-term survival. These data support the development of novel, personalized treatments for locally advanced resectable NSCLC.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Spicer, J. D. et al. Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations From the International Association for the Study of Lung Cancer. J. Thorac. Oncol. 19, 1373–1414 (2024).
Provencio, M. et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 21, 1413–1422 (2020).
Provencio, M. et al. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. Lancet Oncol. 25, 1453–1464 (2024).
Provencio, M. et al. Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: results from the phase 3 CheckMate 77T study. J. Clin. Oncol. 42, LBA8007 (2024).
Spicer, J. et al. Neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. J. Clin. Oncol. 42, LBA8010 (2024).
Forde, P. M. et al. PL02.08 perioperative vs neoadjuvant nivolumab for resectable NSCLC: patient-level data analysis of CheckMate 77T vs CheckMate 816. J. Thorac. Oncol. 19, S2 (2024).
Marinelli, D. et al. Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis. J. Thorac. Oncol. https://doi.org/10.1016/j.jtho.2024.09.1443 (2024).
Reck, M. et al. LBA49 Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): expanded analyses from AEGEAN. Ann. Oncol. 35, S1239 (2024).
Provencio, M. et al. OA12.05 APOLO: phase II trial of induction chemo-immunotherapy plus chemoradiotherapy and maintenance immunotherapy in stage III NSCLC. J. Thorac. Oncol. 19, S37 (2024).
William, W. N., Jr. et al. OA12.06 intensified chemo-immuno-radiotherapy with durvalumab for stage III NSCLCs: a single arm phase II study - PACIFIC-BRAZIL (LACOG 2218). J. Thorac. Oncol. 19, S37–S38 (2024).
Acknowledgements
The work of T.C. is in part supported by the National Institute of Health (NIH)/National Cancer Institute (NCI) through the University of Texas Lung Specialized Program of Research Excellence SPORE grant 5P50CA070907, the NIH/NCI grant R01CA287734, the Mark Foundation for Cancer Research Endeavor Award, the University of Texas MD Anderson Cancer Center Lung Cancer Moon Shot Program, the Rexanna’s Foundation for Fighting Lung Cancer, and the Andrew Sabin Family Foundation Fellowship Award. T.C. and W.N.W.Jr. would like to acknowledge the Bob Mayberry Foundation for their continued support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.C. has acted as a consultant and/or advisor and/or speaker for, and/or has received travel support from ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Clinical Care Options, Daiichi Sankyo, Genentech, IDEOlogy Health, Medical Educator Consortium, Medscape, Merck, OncLive, oNKo-innate, PEAK Medicals, PeerView, Pfizer, Physicians’ Education Resource, RAPT Therapeutics, Regeneron, and Targeted Oncology. W.N.W.Jr. has acted as a consultant and/or advisor and/or speaker for, and/or has received travel support from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Genentech/Roche, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi-Aventis, Takeda and United Medical.
Rights and permissions
About this article
Cite this article
Cascone, T., William, W.N. Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer. Nat Rev Clin Oncol 22, 81–82 (2025). https://doi.org/10.1038/s41571-024-00976-x
Published:
Issue date:
DOI: https://doi.org/10.1038/s41571-024-00976-x
